Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Primary Hyperoxaluria Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 12 Sep 17

The "Primary Hyperoxaluria - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Primary Hyperoxaluria - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Primary Hyperoxaluria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1 and 2 respectively.

Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Primary Hyperoxaluria - Overview
  3. Primary Hyperoxaluria - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Primary Hyperoxaluria - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Primary Hyperoxaluria - Companies Involved in Therapeutics Development
  • Allena Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • Dicerna Pharmaceuticals Inc
  • Intellia Therapeutics Inc
  • OxThera AB

For more information about this report visit https://www.researchandmarkets.com/research/4jpttq/primary

View source version on businesswire.com: http://www.businesswire.com/news/home/20170912006552/en/

Business Wire
www.businesswire.com

Last updated on: 12/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.